Stephanie Jo1, Ronnie Sebro2,3,4,5. 1. Department of Radiology, University of Pennsylvania, Philadelphia, PA, U.S.A. 2. Department of Radiology, University of Pennsylvania, Philadelphia, PA, U.S.A.; Rsebro@gmail.com. 3. Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, U.S.A. 4. Department of Genetics, University of Pennsylvania, Philadelphia, PA, U.S.A. 5. Department of Epidemiology, Biostatistics and Informatics, University of Pennsylvania, Philadelphia, PA, U.S.A.
Abstract
BACKGROUND/AIM: To identify prognostic imaging biomarkers from staging chest computed tomography (CT) in patients with sarcomas. PATIENTS AND METHODS: CT scans for baseline staging, and surveillance 1-year CT scans in patients newly diagnosed with sarcoma were evaluated. Pectoralis muscle area (PMA), pectoralis muscle index (PMI) and pectoralis CT attenuation density (PMT) were measured. Cox proportional-hazard models were used to determine the association with progression-free survival (PFS) and overall survival (OS). RESULTS: There were 147 patients (53.1% male) who were followed for a median 1,414 days (range=219-4851 days). Approximately 47.6% (70/147) of patients progressed and 29.9% (44/147) died. Multivariable Cox-proportional hazards models adjusting for gender, tumor grade and chemotherapy treatment showed that a higher baseline PMT and baseline PMI were associated with increased OS. CONCLUSION: Higher baseline PMI and PMT are associated with increased overall survival in patients with sarcoma.
BACKGROUND/AIM: To identify prognostic imaging biomarkers from staging chest computed tomography (CT) in patients with sarcomas. PATIENTS AND METHODS: CT scans for baseline staging, and surveillance 1-year CT scans in patients newly diagnosed with sarcoma were evaluated. Pectoralis muscle area (PMA), pectoralis muscle index (PMI) and pectoralis CT attenuation density (PMT) were measured. Cox proportional-hazard models were used to determine the association with progression-free survival (PFS) and overall survival (OS). RESULTS: There were 147 patients (53.1% male) who were followed for a median 1,414 days (range=219-4851 days). Approximately 47.6% (70/147) of patients progressed and 29.9% (44/147) died. Multivariable Cox-proportional hazards models adjusting for gender, tumor grade and chemotherapy treatment showed that a higher baseline PMT and baseline PMI were associated with increased OS. CONCLUSION: Higher baseline PMI and PMT are associated with increased overall survival in patients with sarcoma.
Authors: Wael Toama; Jason Wiederin; Ryan Shanley; Patricia Jewett; Christina Gu; Chetan Shenoy; Prabhjot S Nijjar; Anne H Blaes Journal: BMC Cancer Date: 2022-07-13 Impact factor: 4.638